FDA generic biologics document delayed
Executive Summary
Development of FDA background document on generic biologics is delayed while senior management addresses drug safety issues raised during the year. The goal of the document is to harmonize review practices of biologics used to treat different diseases; it was due out in 2004 (1"The Pink Sheet" Nov. 1, 2004, p. 16)...
You may also be interested in...
FDA Follow-On Biologics Background Document To Be Released By Year-End
FDA is developing a background document as part of its ongoing action on "follow-on" biologics, Acting Commissioner for Operations Janet Woodcock, MD, said
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.